Lineage Cell Therapeutics, Inc. news

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has expanded its exist

• 12-Month Primary Endpoint Data Suggest OpRegen is Well Tolerated with an Acceptable Safety Profile
• Preliminary Evidence of Visual Function and Outer Retinal Structure Improvements Observed in Cohort 4 Patients with GA and Impaired Vision
• Data Reported at 2022 ARVO Meeting by Allen C. Ho, M.D., FACS

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced a new cell therapy devel

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that <

• Expansion of Pipeline Into a Third Neuronal Cell Type Builds on Existing Capabilities
• Intellectual Property Has Been Filed Covering Composition and Methods for Generating Auditory Neuronal Progenitors
• Hearing Loss Afflicts More Than 5% of the Population; More Than 430 Million People